Naloxone Hydrochloride Injection

1. Completely or partially correct the central inhibitory effects of opioids. Such as respiratory depression, sedation and hypotension. 2. Has a wake-promoting effect on animals with acute ethanol poisoning. 3. It is a pure opioid receptor antagonist, that is, it does not have the excitatory or morphine-like effects of other opioid receptor antagonists; it does not cause respiratory depression, psychotomimetic reactions or mydriasis reactions. 4. No drug resistance, nor physiological or psychological dependence, has been observed. 5. Although the mechanism of action is not yet fully understood, there is sufficient evidence to show that it antagonizes the effects of opioids by competing for the same receptor sites.

The main component of this product and its chemical name are: 17-allyl-4,5a-epoxy-3,14-dihydroxymorphinan-6-one hydrochloride dihydrate. Its structural formula is: Molecular formula: C19H21NO4HCl2H2O, molecular weight: 399.87.

This product is the most widely used opioid receptor antagonist in clinical practice. It is mainly used for: 1. Rescue acute poisoning by narcotic analgesics, antagonize the respiratory depression of this type of drug, and awaken the patient. 2. Antagonize the residual effects of narcotic analgesics. Newborns are affected by narcotic analgesics in their mothers and suffer respiratory depression, which can be antagonized by this product. 3. Rescue acute ethanol poisoning: intravenous injection of naloxone 0.4-0.6mg can awaken the patient. 4. For those suspected of being addicted to narcotic analgesics, intravenous injection of 0.2-0.4mg can stimulate withdrawal symptoms and has diagnostic value. 5. Awakening effect, which may activate the physiological awakening system through cholinergic effects to awaken the patient, and is used for general anesthesia awakening and anti-shock and some comatose patients.

Common dosage: naloxone 5mg/kg, wait 15 minutes and then intramuscularly inject 10mg/kg. Or first give a loading dose: 1.5-3.5mg/kg, and maintain at 3mg/kggh. In detoxification treatment, intramuscular or intravenous injection: 0.4-0.8mg each time. In the process of methadone withdrawal, you can try a small dose of methadone (5-10mg per day), give naloxone 1.2mg every half hour for several hours (3-6 hours), and then switch to naloxone. Use it 3 times a week to achieve the purpose of withdrawal.

Adverse reactions of this product in postoperative patients are occasionally: hypotension, hypertension, ventricular tachycardia and ventricular fibrillation, dyspnea, pulmonary edema and cardiac arrest. The sequelae of death, coma and encephalopathy have been reported. Overdose of this product in postoperative patients may reverse analgesia and cause patient agitation. Reversal of opioid inhibition A sudden reversal of opioid inhibition may cause nausea, vomiting, sweating, palpitations, increased blood pressure, shivering, seizures, ventricular tachycardia and ventricular fibrillation, pulmonary edema and cardiac arrest, and may even lead to death. Opioid dependence A sudden reversal of the opioid effect in patients who are physically dependent on opioids may cause acute withdrawal syndrome, including but not limited to the following symptoms and signs: body pain, fever, sweating, runny nose, sneezing, piloerection, yawning, weakness, chills or tremors, nervousness, restlessness or irritability, dysentery, nausea or vomiting, abdominal cramps, increased blood pressure, palpitations. In neonates, symptoms of opioid withdrawal may include: convulsions; excessive crying; hyperreflexia. Adverse reactions to postoperative use of this drug and dose reduction are classified by organ system as follows: Cardiac: pulmonary edema, cardiac arrest or failure, hypercardia, ventricular fibrillation, and ventricular tachycardia. Death, coma, and encephalopathy have been reported as sequelae. Gastrointestinal: vomiting, nausea. Nervous: convulsions, paresthesias, grand mal seizures. Psychiatric: agitation, hallucinations, tremors. Respiratory, thoracic, and diaphragmatic: dyspnea, respiratory depression, hypoxia. Skin and subcutaneous injections: nonspecific injection site reactions, sweating. Vascular disorders: hypertension, hypotension, hot flashes or redness.

Patients who are allergic to this product are contraindicated.

Precautions for children: Using this product on children or newborns can reverse the effects of opioids. Children with opioid poisoning have a strong reaction to this product, so they need to be closely monitored for at least 24 hours until this product is completely metabolized.

1. The low binding rate and slow dissociation rate of buprenorphine to opioid receptors determine its long duration of action. Therefore, a large dose of naloxone should be used to antagonize the effects of buprenorphine. The antagonism of buprenorphine needs to be gradually enhanced to reverse the effect and shorten the duration of respiratory depression. 2. Methynilbarbital can block the acute withdrawal symptoms induced by naloxone in opioid addicts. 3. This product should not be mixed with preparations containing sodium bisulfate, sodium bisulfite, long-chain polymer anions or any alkaline. Before adding drugs or chemical reagents to the solution of this product, its effect on the chemical and physical stability of the solution should be determined first.

Keep tightly closed in a cool, dark place.

1ml:1mg

24 months

Hebei Aier Haitai Pharmaceutical Co., Ltd.

• Founded in:

  2006-03-07

• Address:

  No. 219, Taishan Street, Shijiazhuang High-tech Industrial Development Zone

• Tax NO.:

  91130101785718732X

• Registered Funds:

  55.1622 million yuan

• Website:

  Log in to view

• Email:

  Log in to view